7,446 Results

Positive data announced from pivotal Phase III inTandem2 study of LX 4211 (sotagliflozin) in type 1 diabetes- Lexicon Pharma

 Added 18 hours ago

Lexicon Pharmaceuticals announced additional positive data from the pivotal Phase III inTandem2 study of LX 4211 (sotagliflozin), for type 1...

Positive results from CheckMate -214 trial for Opdivo (nivolumab) plus Yervoy (ipilimumab) versus sunitinib as a treatment for renal cell carcinoma. - BMS

 Added 18 hours ago

Bristol-Myers Squibb Company announced topline results today from the CheckMate -214 trial investigating Opdivo (nivolumab) in combination with Yervoy (ipilimumab)...

Shire pLc announces that the UK as reference state has validated the MAA for lifitegrast as a treatment for dry eye disease.

 Added 1 day ago

Shire plc announces that the Marketing Authorization Application (MAA) for lifitegrast, submitted on 7 August 2017, has been validated by...

Mundipharma acquires from Cell Act world rights to CAP7.1. a novel pro-drug of anticancer agent etoposide.

 Added 1 day ago

The Mundipharma network of independent associated companies announced that it has acquired from CellAct the worldwide development,commercialization and manufacturing rights...

The FDA has found the resubmitted Biologics License Application (BLA) from Portola Pharmaceuticals Inc. relating to AndexXa (andexanet alfa) to be acceptable for review.

 Added 1 day ago

Portola Pharmaceuticals Inc. announced that the FDA has found its resubmitted Biologics License Application (BLA) for AndexXa (andexanet alfa) to...

Fovista (pegpleranib) in combination with Eylea (aflibercept) or Avastin (bevacizumab) is not superior to Eylea or Avastin monotherapy for the treatment of wet age-related macular degeneration — Ophthotech Corporation.

 Added 2 days ago

Ophthotech Corporation announced that the pre-specified primary endpoint of mean change in visual acuity at 12 months was not achieved...

GW Pharma has statred a rolling submission at the FDA for Epidiolex (cannabidiol) to treat Dravet syndrome and Lennox-Gastaut syndrome.

 Added 2 days ago

GW Pharmaceuticals PLC,has announced it had started to submit a US NDA for its oral cannabidiol product Epidiolex in two...

NICE does not recommend Kisplyx (lenvatinib) from Eisai and Fotivda (tivozanib) from EUSA as treatments for renal cell carcinoma.

 Added 2 days ago

The National Institute for Health and Care Excellence (NICE) is not recommending Kisplyx (lenvatinib) from Eisai in combination with everolimus...

Suptavumab (REGN 2222) fails Phase III trial to prevent medically-attended RSV infections in infants.- Regeneron.

 Added 2 days ago

Regeneron Pharmaceuticals, Inc.announced that a Phase III study evaluating suptavumab (REGN 2222), an antibody to respiratory syncytial virus (RSV), did...

Load more